Launch of Innovative Sanyou Super-Trillion Antibody Discovery Platform – World Premiere | New
SHANGHAI, June 2, 2022 /PRNewswire/ — Sanyou Biopharmaceuticals officially launched STAL (Super-Trillion Antibody Libraries) on June 3, 2022which is an innovative super trillion-dollar antibody-based drug discovery platform owned by Sanyou intellectual property.
Developed by Sanyou after seven years of continuous innovation and independent R&D, STAL represents a significant breakthrough over the previous generation of the innovative trillion antibody discovery platforms. The STAL Discovery Platform integrates nine categories of innovative super-trillion antibody libraries with an overall library capacity of up to 10 trillion. Screening validations with dozens of targets have shown that thousands of novel antibodies can be discovered through the STAL platform, and the quantity is tens or even hundreds of times greater than that of canonical methods.
Hundreds of millions of patients around the world suffer from cancers, autoimmune diseases, allergic diseases and metabolic diseases every year. Drugs, including monoclonal antibodies, bispecific antibodies, ADC, AOC, RAC, PDC, and CAR-T therapy, are the main treatments for these diseases. More than 100 biologic drugs have been approved with total annual market revenues approaching 200 billion dollars. High specificity antibodies are the common building blocks of these drugs and play an important role in precise targeting.
The STAL discovery platform incorporates phage display and mammalian cell expression technologies, and is complemented by fully automated screening and integrated antibody R&D platforms. STAL is effective in challenging innovative targets and developing very difficult drug modalities. It can meet R&D needs related to the discovery of various innovative biological drugs, including fully human antibodies, humanized single domain antibodies, humanized monoclonal antibodies, bispecific antibodies, multispecific antibodies, polypeptides, ADCs, PDC and miniaturized proteins. The candidates obtained have natural conformations, a high affinity and a great capacity for development.
The STAL discovery platform is based on a customer-oriented, modular, diversified and personalized commercial system, which is applicable not only to the R&D of various innovative biological drugs, but also to the research of disease mechanisms and the development of diagnostic. Dozens of projects from the platform have delivered preclinical candidates, several projects have completed preclinical R&D and entered the clinical phase.
dr. Guojun LangCEO of Sanyou, said, “Innovative drug research and development has gradually entered a difficult era where we have to overcome very difficult innovative targets, new drug modalities, and diseases of intriguing complexity.”
“The STAL Discovery Platform comprises nine super-trillion antibody libraries, with up to hundreds of times the number of lead antibodies compared to canonical antibody discovery technologies. The platform integrates technologies for generating a variety of biological drugs such as fully human antibodies, humanized antibodies, miniaturized nanobodies, affinity polypeptides and affinity miniaturized proteins, so that it is suitable not only for the development of antibodies targeting conventional epitopes, but also the development of antibodies targeting specific epitopes and refined epitopes cell expression technology so that it is not only suitable for cross-screening with proteins from different species such as human , mouse and monkey, but also to positive/negative screening of differentiated proteins such as mutation sites, anticor ps competitors, Fc fusion proteins and His fusion proteins, as well as complexes for screening difficult targets such as cellular antigens, polypeptide antigens and transmembrane antigens.”
“The STAL Discovery Platform has been modularly integrated with the Innovative Antibody R&D Integrated Preclinical Platform. As a result, various antibody discovery services, featured technical services and tiered technical services can be implemented flexibly, and preclinical and integrated candidate discovery Preclinical biological drug R&D can be completed as a one-stop solution.Based on this platform, Sanyou also develops an intelligent and innovative platform of antibody-based drug discovery.
“It is believed that Sanyou’s integrated preclinical innovative antibody R&D platform, STAL discovery platform and intelligent innovative antibody drug discovery platform will greatly help our partners to lead the competition, overcoming difficulties in drug innovations and further developing high-quality innovative drugs for the benefit of patients.”
About Sanyou Biopharmaceuticals
Sanyou Biopharmaceuticals Co., Ltd. is a world-renowned biotechnology and high-tech company that focuses on the R&D and services of innovative antibody drugs.
Sanyou is committed to establishing a high-quality, high-throughput and leading integrated R&D and value transformation platform for innovative antibodies, building a commercial ecosystem including therapy, R&D products and services and diagnostics, and to cooperate with biopharmaceutical, diagnostic, and pharmaceutical R&D companies to make new advances in the diagnosis and treatment of human disease.
Sanyou has set up an innovative antibody research and development integrated laboratory of several thousand square meters with state-of-the-art facilities. There are 10 major functional modules and more than 40 core technology platforms, which are featured by a series of Super-Trillion phage display antibody libraries and integrated platforms covering innovative antibody drug discovery, innovative optimization of antibody drugs, construction of production cell lines, upstream and downstream process development, preclinical R&D and industrial development, etc.
Sanyou has built a business system that integrates “differentiated CRO, innovative CPO and characteristic CRS”, and constantly launches new technologies, new products, new services and new scenarios based on the principle of high quality, fast delivery and profitability. Friendly business collaborations have been established with more than 300 pharmaceutical companies, drug research and development institutes and diagnostic companies all over the world.
View original content to download multimedia: https://www.prnewswire.com/news-releases/sanyou-super-trillion-innovative-antibody-drug-discovery-platform-announced—world-premiere-301560156.html